Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Receivables - Net: 2020-2022

Historic Receivables - Net for Tango Therapeutics (TNGX) over the last 1 years, with Dec 2022 value amounting to $2.0 million.

  • Tango Therapeutics' Receivables - Net changed negligibly% to $2.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $2.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $2.0 million for FY2022, which is negligibly% changed negligibly from last year.
  • Tango Therapeutics' Receivables - Net amounted to $2.0 million in Q4 2022, which was down 0.00% from $2.0 million recorded in Q3 2022.
  • Tango Therapeutics' 5-year Receivables - Net high stood at $8.0 million for Q3 2021, and its period low was $2.0 million during Q4 2020.
  • For the 3-year period, Tango Therapeutics' Receivables - Net averaged around $2.9 million, with its median value being $2.0 million (2022).
  • Data for Tango Therapeutics' Receivables - Net shows a maximum YoY tumbled of 75.00% (in 2022) over the last 5 years.
  • Over the past 3 years, Tango Therapeutics' Receivables - Net (Quarterly) stood at $2.0 million in 2020, then remained steady at $2.0 million in 2021, then remained steady at $2.0 million in 2022.
  • Its Receivables - Net was $2.0 million in Q4 2022, compared to $2.0 million in Q3 2022 and $2.0 million in Q2 2022.